Kyverna Therapeutics, Inc. (KYTX) Guidance & Earnings Results
On 2025-11-12 Kyverna Therapeutics, Inc. raised guidance: "SPS topline data expected early 2026 (narrowed from first half 2026); BLA filing 1H 2026; MG Phase 3 enrollment by year-end 2025; IND for KYV-102 Q4…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYTXKyverna Therapeutics, Inc.Follow KYTX — free
—
Price chart with a free account
- Market cap
- 333.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Nov 25 | Raised | SPS topline data expected early 2026 (narrowed from first half 2026); BLA filing 1H 2026; MG Phase 3 enrollment by year-end 2025; IND for KYV-102 Q4 2025 |
Kyverna Therapeutics, Inc. — questions
- What guidance did Kyverna Therapeutics, Inc. give?
- On 2025-11-12: "SPS topline data expected early 2026 (narrowed from first half 2026); BLA filing 1H 2026; MG Phase 3 enrollment by year-end 2025; IND for KYV-102 Q4 2025"
- When does Kyverna Therapeutics, Inc. report earnings?
- Kyverna Therapeutics, Inc.'s next earnings report is expected on 2026-11-18.
Every figure on this page comes from Kyverna Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.